SHUBHAM PANT to Exanthema
This is a "connection" page, showing publications SHUBHAM PANT has written about Exanthema.
Connection Strength
0.232
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
Score: 0.202
-
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 10 10; 34(29):3562-3569.
Score: 0.030